Aduro BioTech, Inc. Company Review & Valuation

ADRO
Nasdaq
Latest Price
0.00USD
Market Capitalization
0.00USD

About Aduro BioTech, Inc.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases.

The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers.

The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor.

It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck.

The company was formerly known as Oncologic, Inc.

and changed its name to Aduro BioTech, Inc.

in June 2008.

Aduro BioTech, Inc.

was founded in 2000 and is based in Berkeley, California.

Industry
Biotechnology
HQ Location
Berkeley, California

Stock Price

Price data not available for Aduro BioTech, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl